Vortioxetine on Cognition in Schizophrenia: A Pilot Study

Area of Science:

• Psychiatry and Neuroscience
• Pharmacological Interventions
• Cognitive Function Research

Background:

• Cognitive impairment significantly impacts schizophrenia prognosis, with limited effective pharmacological treatments.
• Vortioxetine, a multimodal antidepressant, is being explored for its potential to treat cognitive symptoms in depression.
• Existing treatments for cognitive deficits in schizophrenia remain largely unimpressive.

Purpose of the Study:

• To investigate the efficacy of vortioxetine as an augmentation therapy for cognitive deficits in schizophrenia patients on clozapine.
• To assess the impact of vortioxetine on cognitive functions, positive and negative symptoms, and depressive symptoms.
• To evaluate the safety and tolerability of vortioxetine in this patient population.

Main Methods:

• A 24-week open-label study involving 20 schizophrenia outpatients on stable clozapine treatment.
• Patients received vortioxetine, starting at 10 mg/d and increasing to 20 mg/d.
• Cognitive function was assessed using the Wisconsin Card Sorting Test, Verbal Fluency, and Stroop task; psychopathology was evaluated using the PANSS and Calgary Depression Scale for Schizophrenia.

Main Results:

• Significant improvements were observed in Stroop test performance at week 12 and at the study's end.
• Semantic Fluency also showed significant improvement by the end of the study.
• Reductions in Positive and Negative Syndrome Scale (PANSS) positive symptoms and depressive symptoms were noted, with no significant adverse effects.

Conclusions:

• Vortioxetine augmentation of clozapine appears to be a potentially effective strategy for improving cognitive deficits in schizophrenia patients.
• The study provides preliminary evidence supporting vortioxetine's role in addressing cognitive dysfunction in this population.
• Despite limitations, the findings warrant further investigation in larger, controlled trials.